Cellectis SA (CLLS)
3.75
+0.09
(+2.46%)
USD |
NASDAQ |
Mar 04, 16:00
3.76
+0.01
(+0.27%)
Pre-Market: 20:00
Cellectis Cash from Investing (TTM) : -68.81M for Sept. 30, 2025
Cash from Investing (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (TTM) Benchmarks
| EDAP TMS SA | -- |
| DBV Technologies SA | 0.1363M |
| Ascendis Pharma A/S | -9.612M |
| Akari Therapeutics Plc | 0.382M |
| Biodexa Pharmaceuticals Plc | -0.4065M |